Ovid Therapeutics (OVID) Retained Earnings (2016 - 2026)
Ovid Therapeutics (OVID) posted Retained Earnings of -$338.7 million for Q1 2026, down 167573.76% on a QoQ basis from -$202000.0 in Q4 2025, and down 720540.43% year-over-year from N/an in Q1 2025.
Ovid Therapeutics (OVID) Retained Earnings (2016 - 2026) Analysis & Trends
Ovid Therapeutics' Retained Earnings history runs 11 years deep, the most recent figure standing at -$338.7 million for Q1 2026.
- Quarterly Retained Earnings fell 720540.43% year-over-year to -$338.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$338.7 million (down 720540.43% YoY) and the FY2025 annual result came in at -$202000.0, up 99.93% from the prior year.
- Retained Earnings was -$338.7 million for Q1 2026 at Ovid Therapeutics, down from -$202000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $376.1 million in Q3 2025 and bottomed at -$338.7 million in Q1 2026.
- A 5-year average of -$43.7 million and a median of -$202000.0 in 2025 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings surged 308.79% — and 2024, when it tumbled 30430000.0%.
- Ovid Therapeutics' Retained Earnings stood at $357.8 million in 2022, then plunged by 100.0% to $1000.0 in 2023, then tumbled by 30430000.0% to -$304.3 million in 2024, then surged by 99.93% to -$202000.0 in 2025, then plunged by 167573.76% to -$338.7 million in 2026.
- Business Quant data shows OVID's Retained Earnings at -$338.7 million in Q1 2026, -$202000.0 in Q4 2025, and $376.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | -27.89 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -279.01 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 12.91 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -622,000.00 |
| 10 | Ovid Therapeutics | 118.66 Mn | -36.86 Mn | - | -338.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -338.70 Mn |
| Dec 31, 2025 | -202,000.00 |
| Sep 30, 2025 | 376.13 Mn |
| Jun 30, 2025 | -319.22 Mn |
| Mar 31, 2025 | -47,000.00 |
| Dec 31, 2024 | -304.30 Mn |
| Sep 30, 2024 | -295.05 Mn |
| Jun 30, 2024 | -12,000.00 |
| Mar 31, 2024 | -289.56 Mn |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | -262.50 Mn |
| Jun 30, 2023 | 361.91 Mn |
| Mar 31, 2023 | 359.75 Mn |
| Dec 31, 2022 | 357.77 Mn |
| Sep 30, 2022 | -82,792.00 |
| Jun 30, 2022 | -202.10 Mn |
| Mar 31, 2022 | -187.50 Mn |
| Dec 31, 2021 | -171.36 Mn |
| Sep 30, 2021 | -145.36 Mn |
| Jun 30, 2021 | -134.00 Mn |